Skip to content
naulon

No retraction, correction or concern found when last checked on Oct 23, 2026.

Do Cryptic Reservoirs Threaten Gambiense-Sleeping Sickness Elimination?

Philippe Büscher, Jean-Mathieu Bart, Marleen Boelaert and 25 more

Trends in Parasitology · 2018 · Review · CC BY

doi:10.1016/j.pt.2017.11.008

Abstract

Trypanosoma brucei gambiense causes human African trypanosomiasis (HAT). Between 1990 and 2015, almost 440000 cases were reported. Large-scale screening of populations at risk, drug donations, and efforts by national and international stakeholders have brought the epidemic under control with <2200 cases in 2016. The World Health Organization (WHO) has set the goals of gambiense-HAT elimination as a public health problem for 2020, and of interruption of transmission to humans for 2030. Latent human infections and possible animal reservoirs may challenge these goals. It remains largely unknown whether, and to what extend, they have an impact on gambiense-HAT transmission. We argue that a better understanding of the contribution of human and putative animal reservoirs to gambiense-HAT epidemiology is mandatory to inform elimination strategies.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 23, 2026. Paragraph numbers are ours, so an answer can point at one.

Can Cryptic Reservoirs in Humans and Animals Compromise the Sustainable Elimination of gambiense-HAT?

HAT is caused by two closely related parasites that are transmitted by tsetse flies. Trypanosoma brucei gambiense is responsible for the Western and Central African form of the disease and Trypanosoma brucei rhodesiense occurs in Eastern and Southern Africa – both forms of the disease are usually fatal if untreated. Between 1990 and 2016, a total of 437 971 cases of gambiense-HAT were reported, with a peak of 37 385 cases in 1998i. Thanks to large-scale deployment of a serological screening test (CATT/T. b. gambiense) (see Glossary), drug donations, and intense efforts by national and international stakeholders, this epidemic has been brought under control, with fewer than 2200 cases reported in 2016. This represents a marked reduction in human suffering caused by the disease. Inspired by this progress, the WHO has set elimination of gambiense-HAT as a target for the near future: elimination as a public health problem by 2020 and the interruption of transmission to humans by 2030ii.

The rationale to shift from HAT control to elimination is based on several arguments, such as the epidemiological vulnerability of gambiense-HAT as a presumed anthroponotic infection, historic examples of elimination in several West African foci, the availability of new medicines and diagnostics, the political will of endemic countries, and the commitment of national control programs. Furthermore, a drug donation agreement between pharmaceutical companies and WHO has made treatment freely available to endemic countries.

gambiense-HAT control classically relies on three pillars: vector control, case finding, and treatment. HAT is a vector-borne disease, and the reduction of human–fly contact below a critical threshold would lead to zero transmission. Although vector control is critical to achieve the elimination/eradication goals, in practice, it will be hard to sustain control of all tsetse fly populations in all endemic countries. Vector control being only part of the solution, gambiense-HAT control will continue to rely to a great extent on surveillance, diagnosis, and treatment, both for reducing transmission and for monitoring progress towards these goals.

The introduction of individual rapid diagnostic tests (RDTs) for gambiense-HAT may increase serological screening coverage as they can be performed in remote dispensaries devoid of technical facilities. Thus, they facilitate the integration of passive screening in the health system and play a role in a sustainable surveillance system. However, RDTs also have limitations – like CATT/T. b. gambiense, they only detect antibodies, and their specificity is not 100%. As a consequence, given the adverse effects and logistic constraints of current treatment, individuals who test positive in an RDT or in CATT must undergo microscopic examination of blood or lymph node fluid to confirm the presence of the parasite, followed by a lumbar puncture for stage determination, as different drugs are required to treat early- and late-stage disease. In recent years, the highly toxic melarsoprol regimen, used to treat late-stage disease, has been replaced by a safer, though still rather complex, treatment requiring parenteral administration and hospitalisation. An oral treatment might become available in late 2018, and a single-dose treatment is entering phase III clinical trialsiii.

Whereas HAT elimination by 2020, as a public health problem, seems within reach, the sustained global elimination of HAT appears more challenging. Indeed, as long as the knowledge gaps surrounding the reservoir of T. b. gambiense in interepidemic periods are not filled, the concept of eradication of gambiense-HAT cannot be considered.

We present the current research evidence about potential human and animal T. b. gambiense reservoirs and discuss their importance in the light of the gambiense-HAT elimination goals.

Human Reservoir

Mathematical models show that the sustained transmission of HAT can be explained if a fraction of the HAT cases is systematically missed by the screening operations. Unfortunately, this is the case in many settings as a number of T. b. gambiense infections remain undiagnosed for several reasons. First, not all infected people are reached by screening activities. Second, current diagnostic techniques do not pick up all T. b. gambiense infections due to lack of sensitivity of serological screening tests, of molecular techniques, or of the parasitological confirmation tests. These undiagnosed, yet infected, people will act as a human reservoir of the parasite and might sustain transmission, forming a maintenance population. Still another potential category of human reservoir may consist of latent infections, also called ‘healthy carriers’, who do not always progress to clinical disease, though the relative contribution of these individuals to parasite transmission still needs to be documented (Box 1). These latently infected people may carry trypanosomes for years or even decades, as was first described half a century ago in West Africa, and later in patients refusing treatment in Côte d’Ivoire,. More recently, a HAT case with a latent infection of at least 29 years was documented. Whether latently infected persons transmit the parasite sexually, and whether sexual and congenital transmission plays a significant role in the epidemiology of gambiense-HAT, remains hypothetical. In Guinea, asymptomatic or latent infections were found to have consistently high titres in CATT/T. b. gambiense and to be positive in the immune trypanolysis test, although no parasites could be detected in blood or lymph node fluid during a 2-year follow-up period. This observation is in line with the fact that trypanosomes can survive in the extravascular spaces of diverse organs such as the heart, the central nervous system, and the skin,,. Experimental infections in animals confirmed that parasites may be undetectable in the blood but hidden in different organs and tissues,,,, including the skin, from where they can be ingested by tsetse flies,. It was only recently that researchers began to investigate the underlying host–parasite interaction mechanisms responsible for those latent infections. Microsatellite profiles and genomic sequencing of parasites from latent infections and from clinical HAT patients are indistinguishable, suggesting that the latent infection phenotype is determined primarily by the host rather than by the parasite. Studies on host genetic polymorphism show that tumor necrosis factor-α-308 A, HLA-G UTR-2, APOL1 N264K, and APOL1 G2 are associated with increased risk of infection or with disease progression, while IL10-592 A, IL64339, APOL1 G1, and other polymorphisms in HPR and APOL1 are associated with decreased risk of infection or with latent infection,,,,,. Other studies have found associations between the innate and the adaptive immune response and infection outcome, for example, self-cure and high levels of interleukin-8 (IL-8); latent infection and high levels of IL-6 or specific interferon-γ-producing T cells; disease progression and high levels of IL-10, TNF-α, and sHLA-G,,. In view of the global elimination of HAT, it is of the utmost importance to clarify the extent to which these human reservoirs contribute to the transmission of the parasite and hence to gambiense-HAT persistence and potential resurgence.There is growing evidence that infection with T. b. gambiense does not always follow the classical course of the disease, that is, a first haemolymphatic stage followed by a second stage with central nervous system involvement progressing to death if left untreated (Figure I). These symptomatic HAT patients are characterised by the detection of parasites in any body fluid (P+), detection of specific antibodies against T. b. gambiense Variable Antigen Type LiTat 1.3 or LiTat 1.5 in immune trypanolysis (TL+), and the presence of clinical symptoms. However, long-term follow-up studies in West Africa have shown that a number of infected individuals do not develop the disease and can be classified as having latent infections (i.e., they are healthy carriers). They remain asymptomatic without detectable parasites (P−) for several years, although they are consistently positive in the immune trypanolysis test (TL+). Moreover, some of them may become immune trypanolysis-negative (TL−) over time, suggesting that they self-cured and therefore cannot transmit the parasite any more.Alt-text: Box 1

There is growing evidence that infection with T. b. gambiense does not always follow the classical course of the disease, that is, a first haemolymphatic stage followed by a second stage with central nervous system involvement progressing to death if left untreated (Figure I). These symptomatic HAT patients are characterised by the detection of parasites in any body fluid (P+), detection of specific antibodies against T. b. gambiense Variable Antigen Type LiTat 1.3 or LiTat 1.5 in immune trypanolysis (TL+), and the presence of clinical symptoms. However, long-term follow-up studies in West Africa have shown that a number of infected individuals do not develop the disease and can be classified as having latent infections (i.e., they are healthy carriers). They remain asymptomatic without detectable parasites (P−) for several years, although they are consistently positive in the immune trypanolysis test (TL+). Moreover, some of them may become immune trypanolysis-negative (TL−) over time, suggesting that they self-cured and therefore cannot transmit the parasite any more.

Alt-text: Box 1

Animal Reservoir

Compared to latent infections in humans, our current knowledge of T. b. gambiense infections in animals is very limited and fragmented. The presence of T. b. gambiense in animals has been demonstrated in several studies (Figure 1),. Several authors have suggested that animals can act as a reservoir for gambiense-HAT,,,,,,,,,. In rhodesiense-HAT, sustained parasite transmission cycles exist in both livestock and wildlife, from which the parasite can spill over to humans. For T. b. gambiense, despite early data generated on its infectivity and transmissibility in animals, the epidemiological significance of any animal reservoir is not well understood and may depend on the specific ecosystem of the HAT focus. Even if the parasite can be transmitted to and from animals, factors such as the proportion of blood-feeding on that species by tsetse will determine the epidemiological significance of the species to act as a maintenance population or part of a maintenance community. T. b. gambiense can infect a variety of domestic animals and wildlife, as shown in Table 1. Following infection, most of these animals remain asymptomatic and generally show low to very low parasitaemia. For instance, in pigs infected with a T. b. gambiense strain isolated from a human patient, only xenodiagnosis and blood culture succeeded in revealing an infection but conventional microscopy failed to detect parasites,,,,. Moreover, experimental studies have shown that human-derived T. b. gambiense strains that were cyclically transmitted by tsetse flies between animals for more than a year remained transmissible to humans.

Studying natural T. b. gambiense infections in animals is challenging. Major drawbacks are the usually low parasitaemia and the necessity to distinguish T. b. gambiense from other trypanosome species such as T. brucei brucei, T. congolense, T. vivax, T. suis, and T. simiae. In particular, T. b. gambiense is morphologically identical to the nonhuman infective T. b. brucei. Among the molecular tests, only those targeting the single-copy TgsGP gene are gambiense-specific, thus limiting their analytical sensitivity to >100 trypanosomes per ml of blood,. Biochemical assays, such as isoenzyme profiling, are only applicable on parasite strains that have been isolated and adapted to laboratory rodents or to in vitro cultures,,, and phenotypic assays such as the blood incubation infectivity test are only readily applicable on isolated strains and are not fully gambiense-specific. Tests that detect antibodies against gambiense-specific antigens, such as the variant surface glycoproteins (VSGs) LiTat 1.3 and LiTat 1.5, may be more useful in revealing T. b. gambiense infections in animals. However, the immune trypanolysis test (TL), which is considered 100% specific in humans, still has to be validated in different species of animals. Ancillary information on the T. b. gambiense animal reservoir can be drawn from analysing T. b. gambiense infection in tsetse, in combination with its feeding behaviour, to assess the vectorial transmission of the parasite from the animal reservoir to humans. In summary, there is a need to further improve our tools and increase our understanding regarding the importance of an animal reservoir in gambiense-HAT epidemiology. If further evidence indicates that an animal reservoir may threaten gambiense-HAT elimination, synergy with the control of animal African trypanosomiasis should be considered.

Filling the Knowledge Gaps

The presence of multiple reservoirs is a critical obstacle to the sustained elimination of any infectious agent. For example, when the Guinea worm eradication programme was rolled out, the possibility of an animal reservoir was initially overlooked, but the recent finding of Guinea worm infections in dogs led to the hypothesis that dogs could have acted as a reservoir that caused the reappearance of human cases in Chad. The existence of a human reservoir, in the form of post-kala-azar dermal leishmaniasis, and possibly also latent infections, is a challenge for the sustained elimination of visceral leishmaniasis (VL) from the Indian subcontinent.

The importance of investigating how HAT can re-emerge in so-called silent foci is clearly illustrated by the fact that a 9-year-old child was diagnosed with gambiense-HAT in Ghana in 2013, 10 years after the last detected case. Also, the finding of a gambiense-specific PCR-positive squirrel in Equatorial Guinea on Luba island in 2014, where the last human HAT case was reported in 1995, is worrying. Therefore, in the context of gambiense-HAT elimination, a key question is whether human and/or animal reservoirs are capable of maintaining transmission and causing a resurgence of the disease in different geographical areas and epidemiological settings (see Outstanding Questions).

As with the mathematical modelling of other neglected tropical diseases, models on HAT epidemiology may help to improve our epidemiological knowledge and inform elimination strategies. Models can explore if, and how, animal and human reservoirs could sustain endemicity in HAT foci. However, model predictions heavily depend on the availability of accurate information for their construction, parameterisation, and fitting. To date, a few models have attempted to infer the contribution of reservoirs in gambiense-HAT transmission maintenance by fitting to human epidemiological data. Funk et al. suggested that animals were necessary for persistent transmission in Bipindi focus in Cameroon. Studies of existing gambiense-HAT models in a few foci (i.e., D. R. Congo, Guinea, and Chad) suggest that some type of additional infection reservoir is needed to match the observed dynamics of reported HAT cases,,. This could arise from another human reservoir (including undiagnosed and latent infections), an animal reservoir, and/or heterogeneities in human risk exposure and surveillance coverage. A different modelling exercise considered the implications on transmission and control of whether animals function as reservoirs or as zooprophylaxis but did not address which was more likely.

Due to the current lack of knowledge surrounding latently infected people (including their frequency, disease progression, their relative infectivity to tsetse, and the duration of this infectious stage) modelling latent infections in humans is challenging, and these uncertainties will impact the models’ predictions. In particular, latent infections have only been explicitly incorporated in one gambiense-HAT model, and the potential role of these individuals in maintaining transmission or hindering elimination has yet to be fully analysed. Arguably, long-duration infections, which eventually progress to late-stage disease, are captured by the stage 1 exponential distributions used in many modelling frameworks, but modifications could better represent self-cure and nondetection of latent infections in active screening. Many recent modelling studies have concluded that existing vector-control methods have the ability to quickly reduce transmission to and from tsetse to all hosts, and may be critical for elimination in regions where reservoirs exist,,,,,.

New data and investigations into latent human infections and animal infections will help shape the way in which future models are developed and parameterised by factoring in improved biological evidence. Some critical gaps in our knowledge, which influence modelling choices, are shown in Figure 2 (Key Figure). As well as refining formulation and parameterisation of the existing deterministic models, it is also clear that a new generation of models is needed. Stochastic models are better suited to capture the chance events that determine the role of cryptic reservoirs and their implications for elimination. In conclusion, improved mathematical models on HAT epidemiology, combined with additional field and experimental data, are needed to help understand the respective roles of these reservoirs.

Concluding Remarks

We believe that attaining the elimination (zero transmission) target of gambiense-HAT by 2030 is feasible but, as observed for other neglected tropical diseases, latent infections – whether human or animal – may constitute cryptic parasite reservoirs and thus add another challenge to sustained elimination. To inform evidence-based elimination strategies, a better understanding of the contribution of these putative human and animal reservoirs on the epidemiology of gambiense-HAT is required, more in particular on (i) the frequency and duration of latent human infections and infections in animals, (ii) the infectiveness of latent human infections and animal reservoirs to tsetse flies, (iii) the ability of latent human infections or animal reservoirs to sustain transmission in interepidemic periods, and (iv) the possible existence of an animal transmission cycle in the absence of human transmission and its ability to seed a new transmission cycle in humans. To investigate these issues, we urgently need to improve our toolbox for the identification of latent and self-cured infections, including prognostic and diagnostic markers. Also, more accurate and preferably high-throughput tests to detect and monitor T. b. gambiense infections in animals should be developed, along with improved mathematical models for exploration of epidemiological hypotheses.How frequent are latent infections with T. b. gambiense in humans and in animals?What is the duration of latent infection in humans and in animals?How infective are latent human infections and animal reservoirs to tsetse flies?Are latent human infections or animal reservoirs capable of sustaining transmission in interepidemic periods?Is it possible to discriminate ongoing latent infection from self-cure in humans?Do prognostic markers of latent infection outcome in humans exist?What are the intrinsic and extrinsic factors that influence latent infection outcome in humans?Can, and do, animal transmission cycles of T. b. gambiense exist in the absence of human transmission? If so, what is the likelihood that they could seed a new transmission cycle in humans?

How frequent are latent infections with T. b. gambiense in humans and in animals?

What is the duration of latent infection in humans and in animals?

How infective are latent human infections and animal reservoirs to tsetse flies?

Are latent human infections or animal reservoirs capable of sustaining transmission in interepidemic periods?

Is it possible to discriminate ongoing latent infection from self-cure in humans?

Do prognostic markers of latent infection outcome in humans exist?

What are the intrinsic and extrinsic factors that influence latent infection outcome in humans?

Can, and do, animal transmission cycles of T. b. gambiense exist in the absence of human transmission? If so, what is the likelihood that they could seed a new transmission cycle in humans?

References 81

  1. 1.

    Büscher P. Human African trypanosomiasis. Lancet. 2017;390:2397-2409.

    Not in our library10.1016/s0140-6736(17)31510-6

  2. 2.

    World Health Organization. Control and surveillance of human African trypanosomiasis. WHO Tech. Rep. Series. 2013;984:1-237.

    Not in our library

  3. 3.

    Jamonneau V. Accuracy of individual rapid tests for serodiagnosis of gambiense sleeping sickness in West Africa. PLoS Negl. Trop. Dis. 2015;9.

    Not in our library10.1371/journal.pntd.0003480

  4. 4.

    Mesu V.K.B.K. Oral fexinidazole for late-stage African Trypanosoma brucei gambiense trypanosomiasis: a pivotal multicentre, randomised, non-inferiority trial. Lancet. 2017.

    Not in our library10.1016/s0140-6736(17)32758-7

  5. 5.

    Rock K.S. Quantitative evaluation of the strategy to eliminate human African trypanosomiasis in the Democratic Republic of Congo. Parasit. Vectors. 2015;8:532.

    Not in our library10.1186/s13071-015-1131-8

  6. 6.

    Robays J. The effectiveness of active population screening and treatment from sleeping sickness control in the Democratic republic of Congo. Trop. Med. Int. Health. 2004;9:542-550.

    Not in our library10.1111/j.1365-3156.2004.01240.x

  7. 7.

    Mumba Ngoyi D. Performance of parasitological and molecular techniques for the diagnosis and surveillance of gambiense sleeping sickness. PLoS Negl. Trop. Dis. 2014;8.

    Not in our library10.1371/journal.pntd.0002954

  8. 8.
  9. 9.
  10. 10.

    Fromentin H. Nouvelles précision sur le Trypanosome sp souche FEO. Ann. Soc. Belg. Méd. Trop. 1963;5:797-800.

    Not in our library

  11. 11.

    Sudarshi D. Human African trypanosomiasis presenting at least 29 years after infection-What can this teach us about the pathogenesis and control of this neglected tropical disease? PLoS Negl. Trop. Dis. 2014;8.

    Not in our library10.1371/journal.pntd.0003349

  12. 12.

    Rocha G. Possible cases of sexual and congenital transmission of sleeping sickness. Lancet. 2004;363:247.

    Not in our library10.1016/s0140-6736(03)15345-7

  13. 13.

    Welburn S.C. Beyond tsetse – Implications for research and control of human African trypanosomiasis epidemics. Trends Parasitol. 2016;32:230-241.

    Not in our library10.1016/j.pt.2015.11.008

  14. 14.

    Ilboudo H. Diversity of response to Trypanosoma brucei gambiense infections in the Forecariah mangrove focus (Guinea): perspectives for a better control of sleeping sickness. Microbes Infect. 2011;13:943-952.

    Not in our library10.1016/j.micinf.2011.05.007

  15. 15.

    Kristensson K., Bentivoglio M., Dumas M. Pathology of African trypanosomiasis. Progress in Human African Trypanosomiasis, Sleeping Sickness. 1999;157-181.

    Not in our library

  16. 16.

    Blum J.A. Cardiac involvement in African and American trypanosomiasis. Lancet Infect. Dis. 2008;8:631-641.

    Not in our library10.1016/s1473-3099(08)70230-5

  17. 17.

    Mcgovern T.W. Cutaneous manifestations of African trypanosomiasis. Arch. Dermatol. 1995;131:1178-1182.

    Not in our library

  18. 18.
  19. 19.

    Giroud C. Murine models for Trypanosoma brucei gambiense disease progression-from silent to chronic infections and early brain tropism. PLoS Negl. Trop. Dis. 2009;3.

    Not in our library10.1371/journal.pntd.0000509

  20. 20.

    Claes F. Bioluminescent imaging of Trypanosoma brucei shows preferential testis dissemination which may hamper drug efficacy in sleeping sickness patients. PLoS Negl. Trop. Dis. 2009;3.

    Not in our library10.1371/journal.pntd.0000486

  21. 21.

    Biteau N. Trypanosoma brucei gambiense infections in mice lead to tropism to the reproductive organs, and horizontal and vertical transmission. PLoS Negl. Trop. Dis. 2016;10.

    Not in our library10.1371/journal.pntd.0004350

  22. 22.
  23. 23.
  24. 24.

    Kabore J. Population genetic structure of Guinea Trypanosoma brucei gambiense isolates according to host factors. Infect. Genet. Evol. 2011;11:1129-1135.

    Not in our library10.1016/j.meegid.2011.04.011

  25. 25.

    Courtin D. Association between human African trypanosomiasis and the IL6 gene in a Congolese population. Infect. Genet. Evol. 2007;7:60-68.

    Not in our library10.1016/j.meegid.2006.04.001

  26. 26.

    Courtin D. Interest of tumor necrosis factor-alpha -308 G/A and interleukin-10 -592C/A polymorphisms in human African trypanosomiasis. Infect. Genet. Evol. 2006;6:123-129.

    Not in our library10.1016/j.meegid.2005.03.002

  27. 27.

    Cuypers B. Apolipoprotein L1 variant associated with increased susceptibility to trypanosome Infection. mBio. 2016;7.

    Not in our library10.1128/mbio.02198-15

  28. 28.

    Courtin D. HLA-G 3′ UTR-2 haplotype is associated with human African trypanosomiasis susceptibility. Infect. Genet. Evol. 2013;17:1-7.

    Not in our library10.1016/j.meegid.2013.03.004

  29. 29.

    Hardwick R.J. Haptoglobin (HP) and haptoglobin-related protein (HPR) copy number variation, natural selection, and trypanosomiasis. Hum. Genet. 2014;133:69-83.

    Not in our library10.1007/s00439-013-1352-x

  30. 30.

    Cooper A. APOL1 renal risk variants have contrasting resistance and susceptibility associations weith African trypanosomiasis. eLIFE. 2017;6.

    Not in our library10.7554/elife.25461

  31. 31.

    Ilboudo H. Trypanosome-induced Interferon-gamma production in whole blood stimulation assays is associated with latent Trypanosoma brucei gambiense infections. Microbes Infect. 2016;18:436-440.

    Not in our library10.1016/j.micinf.2016.03.002

  32. 32.

    Ilboudo H. Unravelling human trypanotolerance: IL8 is associated with infection control whereas IL10 and TNFalpha are associated with subsequent disease development. PLoS Pathog. 2014;10.

    Not in our library10.1371/journal.ppat.1004469

  33. 33.

    Gineau L. Human Leukocyte Antigen-G: a promising prognostic marker of disease progression to improve the control of human African trypanosomiasis. Clin. Infect. Dis. 2016;63:1189-1197.

    Not in our library10.1093/cid/ciw505

  34. 34.

    Cecchi G. Assembling a geospatial database of tsetse-transmitted animal trypanosomosis for Africa. Parasit. Vectors. 2014;7:39.

    Not in our library10.1186/1756-3305-7-39

  35. 35.

    Cecchi G. Developing a continental atlas of the distribution and trypanosomal infection of tsetse flies (Glossina species). Parasit. Vectors. 2015;8:284.

    Not in our library10.1186/s13071-015-0898-y

  36. 36.

    Yesufu H.M. Experimental transmission of Trypanosoma gambiense in domestic animals. Ann. Trop. Med. Parasitol. 1971;65:341-347.

    Not in our library10.1080/00034983.1971.11686763

  37. 37.

    Molyneux D.H. Animal reservoirs and Gambian trypanosomiasis. Ann. Soc. Belg. Med. Trop. 1973;53:605-618.

    Not in our library

  38. 38.

    Kageruka P. Réservoir animal de Trypanosoma (Trypanozoon) brucei gambiense en Afrique Centrale. Ann. Soc. Belg. Méd. Trop. 1989;69:155-163.

    Not in our library

  39. 39.

    Van Hoof L. Sur le rôle du porc comme réservoir de Trypanosoma gambiense. C. R. Soc. Biol. 1937;126:72-75.

    Not in our library

  40. 40.

    Greggio J. A propos de la trypanose des porcs dans la vallée de l'Inkisi. Bull. Agr. Congo Belge. 1917;1–2:148-160.

    Not in our library

  41. 41.

    Jamonneau V. Mixed infections of trypanosomes in tsetse and pigs and their epidemiological significance in a sleeping sickness focus of Côte d'Ivoire. Parasitology. 2004;129:693-702.

    Not in our library10.1017/s0031182004005876

  42. 42.

    Njiokou F. Wild fauna as a probable animal reservoir for Trypanosoma brucei gambiense in Cameroon. Infect. Genet. Evol. 2006;6:147-153.

    Not in our library10.1016/j.meegid.2005.04.003

  43. 43.

    Cordon-Obras C. Molecular evidence of a Trypanosoma brucei gambiense sylvatic cycle in the human african trypanosomiasis foci of Equatorial Guinea. Front. Microbiol. 2015;6:765.

    Not in our library10.3389/fmicb.2015.00765

  44. 44.

    Mehlitz D. The behaviour in the blood incubation infectivity test of four Trypanozoon strains isolated from pigs in Liberia. Trans. R. Soc. Trop. Med. Hyg. 1977;71:86.

    Not in our library10.1016/0035-9203(77)90217-6

  45. 45.

    N’Djetchi M.K. The study of trypanosome species circulating in domestic animals in two human African trypanosomiasis foci in Côte d'Ivoire identifies pigs and cattle as potential reservoirs of Trypanosoma brucei gambiense. PLoS Negl. Trop. Dis. 2017;11.

    Not in our library10.1371/journal.pntd.0005993

  46. 46.
  47. 47.

    Van Hoof L. Recherche sur le comportement de Trypanosoma gambiense chez le porc. Ann. Soc. Belg. Med. Trop. 1940;20:203-228.

    Not in our library

  48. 48.

    Van Hoof L.M.J.J. Observations on trypanosomiasis in the Belgian Congo. Trans. R. Soc. Trop. Med. Hyg. 1947;40:728-761.

    Not in our library

  49. 49.

    Corson J.F. A third note on a strain of Trypanosoma gambiense transmitted by Glossina morsitans. Ann. Trop. Med. Parasitol. 1938;32:245-248.

    Not in our library

  50. 50.

    Duke N.L. Antelope and their relation to trypanosomiasis. Proc. R. Soc. Lond. B. 1913;85:156-169.

    Not in our library

  51. 51.

    Wombou Toukam C.M. Experimental evaluation of xenodiagnosis to detect trypanosomes at low parasitaemia levels in infected hosts. Parasite. 2011;18:295-302.

    Not in our library10.1051/parasite/2011184295

  52. 52.

    Radwanska M. Novel primer sequences for a polymerase chain reaction-based detection of Trypanosoma brucei gambiense. Am. J. Trop. Med. Hyg. 2002;67:289-295.

    Not in our library10.4269/ajtmh.2002.67.289

  53. 53.

    Gibson W. Conserved sequence of the TgsGP gene in Group 1 Trypanosoma brucei gambiense. Infect. Genet. Evol. 2010;10:453-458.

    Not in our library10.1016/j.meegid.2010.03.005

  54. 54.

    Gibson W. The identification of Trypanosoma brucei gambiense in Liberian pigs and dogs by isoenzymes and by resistance to human plasma. Tropenmed. Parasitol. 1978;29:335-345.

    Not in our library

  55. 55.

    Truc P. Multilocus isozyme identification of Trypanosoma brucei stocks isolated in Central Africa: evidence for an animal reservoir of sleeping sickness in Congo. Acta Trop. 1991;49:127-135.

    Not in our library10.1016/0001-706x(91)90060-w

  56. 56.

    Zillmann U. Identity of Trypanozoon stocks isolated from man and a domestic dog in Liberia. Tropenmed. Parasitol. 1984;35:105-108.

    Not in our library

  57. 57.

    Rickman L.R. Observations on the subspecific identification of Trypanosoma (Trypanozoon) brucei isolates from non-human hosts by the blood incubation infectivity test (BIIT). Trans. R. Soc. Trop. Med. Hyg. 1976;70:262-264.

    Not in our library10.1016/0035-9203(76)90063-8

  58. 58.

    Simo G. Tsetse fly host preference from sleeping sickness foci in Cameroon: epidemiological implications. Infect. Genet. Evol. 2008;8:34-39.

    Not in our library10.1016/j.meegid.2007.09.005

  59. 59.

    Diall O. Developing a progressive control pathway for African animal trypanosomosis. Trends Parasitol. 2017;33:499-509.

    Not in our library10.1016/j.pt.2017.02.005

  60. 60.

    Centers for Disease Control and Prevention. Recommendations of the International Task Force for Disease Eradication. 1993;1-39.

    Not in our library

  61. 61.

    Callaway E. Dogs thwart effort to eradicate Guinea worm. Nature. 2016;529:10-11.

    Not in our library10.1038/529010a

  62. 62.

    Singh O.P. Elimination of visceral leishmaniasis on the Indian subcontinent. Lancet Infect. Dis. 2016;16:e304-e309.

    Not in our library10.1016/s1473-3099(16)30140-2

  63. 63.

    Franco J.R. Monitoring the elimination of human African trypanosomiasis: update to 2014. PLoS Negl. Trop. Dis. 2017;11.

    Not in our library10.1371/journal.pntd.0005585

  64. 64.

    Hollingsworth T.D. Quantitative analyses and modelling to support achievement of the 2020 goals for nine neglected tropical diseases. Parasit. Vectors. 2015;8:630.

    Not in our library10.1186/s13071-015-1235-1

  65. 65.

    Rock K.S. Mathematical models of human african trypanosomiasis epidemiology. Adv. Parasitol. 2015;87:53-133.

    Not in our library10.1016/bs.apar.2014.12.003

  66. 66.

    Joshua R.A. Isolation of human serum resistant Trypanozoon from cattle in Nigeria. Tropenmed. Parasitol. 1983;34:201-202.

    Not in our library

  67. 67.

    Pandey A. Evaluating long-term effectiveness of sleeping sickness control measures in Guinea. Parasit. Vectors. 2015;8:550.

    Not in our library10.1186/s13071-015-1121-x

  68. 68.

    Mahamat M.H. Adding tsetse control to medical activities contributes to decreasing transmission of sleeping sickness in the Mandoul focus (Chad). PLoS Negl. Trop. Dis. 2017;11.

    Not in our library10.1371/journal.pntd.0005792

  69. 69.

    Stone C.M., Chitnis N. Implications of heterogeneous biting exposure and animal hosts on Trypanosomiasis brucei gambiense transmission and control. PLoS Comput. Biol. 2015;11.

    Not in our library10.1371/journal.pcbi.1004514

  70. 70.
  71. 71.

    Sutherland C.S. Seeing beyond 2020: an economic evaluation of contemporary and emerging strategies for elimination of Trypanosoma brucei gambiense. Lancet Glob. Health. 2017;5:e69-e79.

    Not in our library10.1016/s2214-109x(16)30237-6

  72. 72.

    Rock K.S. Predicting the impact of intervention strategies for sleeping sickness in two high-endemicity health zones of the Democratic Republic of Congo. PLoS Negl. Trop. Dis. 2017;11.

    Not in our library10.1371/journal.pntd.0005162

  73. 73.

    Thomas H.W., Linton S.F. A comparison of the animal reactions of the trypanosomes of Uganda and Congo Free State sleeping sickness with those of Trypanosoma gambiense (Dutton). Lancet. 1904;1337-1340.

    Not in our library

  74. 74.

    Moloo S.K. Cyclical development of Trypanosoma brucei gambiense from cattle and goats in Glossina. Acta Trop. 1986;43:407-408.

    Not in our library

  75. 75.

    Mesnil F., Blanchard M. Infections des poules dues aux Trypanosoma gambiense et Tryp rhodesiense. C. R. Soc. Biol. 1912;72:938-940.

    Not in our library

  76. 76.

    Watson, H.J.C. (1962). The domestic pig as a reservoir of T. gambiense In 9th Meeting of the International Scientific Council for Trypanosomiasis Research and Control, Conakry, Guinea (Commission de Coopération Technique en Afrique au Sud du Sahara, ed), p. 327

    Not in our library

  77. 77.

    Bouteille B., Dumas M. Experimental models for new chemotherapeutic approaches to human African trypanosomiasis. Progress in Human African Trypanosomiasis, Sleeping Sickness. 1999;289-300.

    Not in our library

  78. 78.

    Godfrey D.G., Killick-Kendrick R. Cyclically transmitted infections of Trypanosoma brucei, T: rhodesiense and T. gambiense in chimpanzees. Trans. R. Soc. Trop. Med. Hyg. 1967;61:781-791.

    Not in our library10.1016/0035-9203(67)90035-1

  79. 79.

    Lucasse C. Fluorescent antibody test as applied to cerebrospinal fluid in human sleeping sickness. Bull. Soc. Pathol. Exot. Fil. 1964;57:283-292.

    Not in our library

  80. 80.

    Frézil J.-L. Etude du comportement de Trypanosoma brucei gambiense sur petits rongeurs et lémuriens du Congo. Cah. ORSTOM Sér. Entomol. Méd. Parasitol. 1979;12:119-126.

    Not in our library

  81. 81.

    Larivière M. Réceptivité de Cricetomys gambianus au Trypanosoma gambiense. C. R. Soc. Biol. 1957;151:1349-1351.

    Not in our library

Cited by papers we hold 5

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.